Litigation Details for AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2021)

AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2021)

Docket		Date Filed	2021-07-02
Court	District Court, D. Delaware	Date Terminated	2022-04-25
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,183,020
Link to Docket	External link to docket

Details for AstraZeneca AB v. Alembic Pharmaceuticals Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-02				External link to document
2021-07-02	15	Judgment - Consent	assigns, is enjoined from infringing U.S. Patent No. 10,183,020, on its own part or through any Affiliate…2021 25 April 2022 1:21-cv-00982 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-07-02	16	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,183,020. (Attachments: # 1…2021 25 April 2022 1:21-cv-00982 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AstraZeneca AB v. Alembic Pharmaceuticals Limited, 1:21-cv-00982: Litigation Summary and Patent Analysis

Last updated: August 18, 2026

AstraZeneca AB sued Alembic Pharmaceuticals Limited in the U.S. District Court for the District of Delaware after Alembic filed an Abbreviated New Drug Application seeking approval for a generic version of Farxiga, AstraZeneca’s dapagliflozin product. The case concerned Orange Book-listed patents covering dapagliflozin compositions, crystalline forms, and therapeutic uses. It was an ANDA Paragraph IV patent dispute, not a biologic or biosimilar action.

What drug and patents were involved in AstraZeneca v. Alembic?

The dispute involved Farxiga, whose active ingredient is dapagliflozin, a sodium-glucose cotransporter 2, or SGLT2, inhibitor used for type 2 diabetes, heart failure, and chronic kidney disease.

Item	Detail
Reference drug	Farxiga
Active ingredient	Dapagliflozin, marketed as dapagliflozin propanediol
NDA holder	AstraZeneca Pharmaceuticals LP
Patent owner in litigation	AstraZeneca AB
Generic applicant	Alembic Pharmaceuticals Limited
Regulatory pathway	ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-00982
Filing period	2021
Dispute type	Hatch-Waxman Paragraph IV patent litigation

The asserted patents were part of AstraZeneca’s Farxiga patent estate. The litigation focused on patents that extended protection beyond the earliest basic dapagliflozin composition patents.

The relevant Farxiga patent family has included patents directed to:

• dapagliflozin crystalline forms;
• pharmaceutical compositions;
• treatment of diabetes;
• treatment of heart failure;
• treatment of chronic kidney disease; and
• combinations with other glucose-lowering agents.

Public FDA Orange Book records identify multiple patents associated with Farxiga and related dapagliflozin products. The precise patents asserted against Alembic must be read from the operative complaint and subsequent amended pleadings because the Orange Book listing and the patents selected for assertion can differ.

Why did AstraZeneca sue Alembic?

AstraZeneca filed the case after receiving notice that Alembic had submitted an ANDA containing a Paragraph IV certification. That certification asserted that one or more Farxiga patents were invalid, unenforceable, or would not be infringed by Alembic’s proposed generic product.

Under the Hatch-Waxman Act, an ANDA applicant may challenge listed patents before expiration. The patent owner then has 45 days after receiving the Paragraph IV notice to file suit. A timely action generally triggers an automatic FDA approval stay of up to 30 months, subject to earlier termination or modification by the court.

AstraZeneca’s lawsuit sought:

1. a declaration that Alembic’s proposed product would infringe the asserted patents;
2. an order prohibiting FDA approval before patent expiration;
3. an injunction against commercial manufacture, use, sale, or importation; and
4. costs and other relief available under the Patent Act.

The case therefore addressed the launch timing of a generic dapagliflozin product rather than damages from an existing commercial launch.

What was the Paragraph IV challenge?

Alembic’s ANDA certification placed the burden on AstraZeneca to prove infringement under the patent claims asserted in the complaint. The infringement analysis likely depended on the proposed product’s:

• dapagliflozin active pharmaceutical ingredient;
• salt or crystalline form;
• formulation and dosage strength;
• labeling;
• indications included in the proposed prescribing information; and
• manufacturing process, where process limitations appeared in the asserted claims.

Method-of-use claims can be particularly important in SGLT2 litigation. A generic applicant may attempt to avoid infringement by carving out a patented indication from its labeling. That approach is known as a section viii statement or skinny label. It is less effective where the patent claims cover the drug composition itself or a broad method that corresponds to the remaining approved uses.

Farxiga presented a substantial method-of-use issue because the product’s approved indications expanded over time. Farxiga was initially associated with type 2 diabetes. FDA approvals later covered cardiovascular and renal indications, including heart-failure and chronic-kidney-disease populations. Each additional indication created potential patent and labeling issues.

What is the Orange Book status of Farxiga?

Farxiga’s Orange Book protection was based on a layered patent estate rather than one single patent. The core dapagliflozin patents had different expiration dates, and later patents could cover specific forms, uses, or indications.

Representative Farxiga-related patents have included the following categories:

Patent category	Commercial relevance
Basic dapagliflozin composition patents	Established the original chemical protection
Crystalline-form patents	Protected the commercial solid form used in tablets
Formulation patents	Addressed tablet composition and pharmaceutical presentation
Diabetes method patents	Covered treatment of type 2 diabetes
Heart-failure method patents	Extended protection to cardiovascular use
Kidney-disease method patents	Covered chronic kidney disease treatment
Combination-treatment patents	Protected use with other therapies

The earliest foundational patents were approaching or had reached expiration by the time of the 2021 litigation. AstraZeneca’s commercial protection therefore depended heavily on later-issued patents and the enforceability of use-specific claims.

When does Farxiga lose exclusivity?

Farxiga’s effective generic-entry date depends on four variables:

1. the expiration date of each asserted patent;
2. any pediatric exclusivity attached to a listed patent;
3. the outcome or settlement of the Paragraph IV case; and
4. whether the generic label excludes patented indications.

Patent expiration does not automatically produce unrestricted generic competition if later patents remain enforceable and cover the approved product or its labeling. Conversely, a generic may launch before the last listed patent expires if it obtains a favorable judgment, reaches a license settlement, or markets a product with an appropriately carved-out label.

For Farxiga, the commercial exposure was concentrated in the later patent estate. Dapagliflozin’s older compound protection did not by itself resolve the litigation because AstraZeneca asserted later patents intended to delay or restrict generic entry.

How strong was AstraZeneca’s patent estate?

AstraZeneca’s estate had meaningful commercial strength but also material litigation vulnerabilities.

Strengths

The principal strength was the breadth of protection surrounding a high-volume product. The estate did not rely solely on a single chemical patent. It included patents potentially covering the active ingredient’s solid form, tablet formulation, treatment methods, and newer indications.

The expansion of Farxiga into heart failure and chronic kidney disease increased the value of method-of-use patents. These indications represented clinically important markets and could support continued branded sales even after diabetes-related competition began.

AstraZeneca also benefited from the practical difficulty of designing around composition and crystalline-form claims while maintaining a commercially acceptable generic product.

Vulnerabilities

The estate faced several risks:

• older foundational patents were nearing expiration;
• method-of-use claims could be vulnerable to invalidity challenges;
• skinny-label strategies could reduce infringement exposure;
• separate patents had to be enforced against each ANDA applicant;
• later-issued indication patents could face written-description, enablement, obviousness, or double-patenting challenges; and
• generic applicants could launch after a favorable judgment on only one dispositive patent.

The strength of the case therefore depended on the exact claim language, the ANDA formulation, the proposed label, and the validity record for each asserted patent.

What was the litigation status?

AstraZeneca AB v. Alembic Pharmaceuticals Limited was filed in the District of Delaware as Case No. 1:21-cv-00982. The matter was an ANDA action and was handled as patent litigation under the Hatch-Waxman framework.

The public docket should be distinguished from related Farxiga cases against other ANDA applicants. AstraZeneca filed multiple actions involving dapagliflozin products, and procedural outcomes in one defendant’s case do not automatically establish the result in another defendant’s case.

The key case-status questions are:

• whether the 30-month FDA stay was triggered;
• which patents remained in the case after claim construction or motion practice;
• whether the parties entered a confidential settlement;
• whether the action was dismissed with prejudice;
• whether Alembic received a licensed launch date; and
• whether the case ended through a consent judgment or an adjudicated invalidity or noninfringement decision.

A dismissal in a Hatch-Waxman case does not necessarily mean that the generic launched immediately. Many cases end through confidential settlements that permit a future launch date before the final patent expiry date but after the settlement date.

Did AstraZeneca and Alembic enter a settlement agreement?

The publicly available docket record must be reviewed for the final dismissal order, stipulation, or consent judgment to determine whether the parties entered a settlement and whether it contained a licensed entry date.

Settlement terms in ANDA litigation are frequently confidential. Public filings may disclose only that the parties stipulated to dismissal. Unless the agreement or a court filing states the authorized launch date, the settlement’s commercial effect cannot be inferred reliably from the docket alone.

For competitive analysis, the critical settlement provisions would be:

• the earliest permitted Alembic launch date;
• whether the license covered all dapagliflozin strengths;
• whether the license covered all approved indications;
• whether an authorized-generic arrangement existed;
• whether AstraZeneca retained supply or manufacturing rights;
• whether the agreement included a no-challenge clause; and
• whether the settlement applied to future patents or only the patents asserted in the case.

What generic launch risks existed for AstraZeneca?

The principal risk was an at-risk launch following a successful invalidity or noninfringement ruling. If Alembic prevailed on the asserted patents, it could seek FDA approval without waiting for those patents to expire. AstraZeneca could then face rapid price erosion across the Farxiga market.

A second risk involved partial-label entry. Alembic could potentially market dapagliflozin for non-patented uses while excluding protected indications. This would reduce, but not eliminate, AstraZeneca’s exposure.

A third risk came from multiple generic applicants. Even if AstraZeneca settled with Alembic, other ANDA filers could continue litigating. A single favorable judgment against another defendant could materially alter the entry landscape.

The commercial impact would depend on the number of approved generic manufacturers, launch timing, payer substitution, and whether the generic product covered diabetes, heart failure, chronic kidney disease, or only selected indications.

How does Farxiga compare with other AstraZeneca patent estates?

Farxiga differs from AstraZeneca’s oncology products such as Tagrisso and Lynparza because small-molecule SGLT2 products face broad generic substitution once composition and formulation barriers fall away. Oncology products may retain stronger use-specific protection and higher clinical switching friction, while diabetes drugs generally face faster payer-driven substitution after generic entry.

Farxiga also differs from biologic products because no biosimilar pathway applies. Alembic’s product was an ANDA generic, and the relevant legal framework was Hatch-Waxman, not the Biologics Price Competition and Innovation Act.

Does biosimilar risk apply to this case?

No. Farxiga is a small-molecule drug. The case involved generic-drug entry through an ANDA and Paragraph IV certification. Biosimilar concepts such as interchangeability, reference-product exclusivity under the Public Health Service Act, and biologic licensing applications were not central to the dispute.

Key Takeaways

• AstraZeneca AB v. Alembic Pharmaceuticals Limited, 1:21-cv-00982, was a Delaware Hatch-Waxman case involving an Alembic ANDA for generic dapagliflozin.
• The reference product was Farxiga.
• AstraZeneca relied on a layered patent estate covering dapagliflozin forms, formulations, and therapeutic uses.
• The dispute concerned Paragraph IV patent challenges and potential generic entry, not biosimilar substitution.
• Later patents covering heart failure and chronic kidney disease were commercially important because they extended protection beyond the original diabetes market.
• A public dismissal or settlement does not, by itself, establish Alembic’s launch date.
• The decisive commercial issue was whether Alembic received a licensed entry date and whether its label included or excluded patented indications.

FAQs About AstraZeneca v. Alembic and Farxiga Patent Litigation

What company filed the Farxiga ANDA involved in Case No. 1:21-cv-00982?

Alembic Pharmaceuticals Limited filed the ANDA that triggered AstraZeneca’s Paragraph IV litigation in the District of Delaware.

Is dapagliflozin protected by formulation patents?

Yes. Farxiga-related protection has included patents directed to the commercial dapagliflozin form and pharmaceutical compositions, in addition to method-of-use patents.

Can a generic launch Farxiga for diabetes while excluding heart-failure use?

Potentially. A generic applicant may use a section viii statement to omit a patented indication, but the legality depends on the precise patent claims, FDA labeling, promotional conduct, and remaining non-patented uses.

What is the main litigation risk from Farxiga generics?

The main risk is rapid price erosion after a generic obtains approval for a commercially meaningful label. Multiple generic approvals can accelerate payer substitution and reduce branded market share.

Does a Farxiga settlement necessarily disclose the generic launch date?

No. ANDA settlements are often confidential. The launch date may be stated in a public court order, but it cannot be assumed from a dismissal alone.

References

1. AstraZeneca AB v. Alembic Pharmaceuticals Limited, No. 1:21-cv-00982, U.S. District Court for the District of Delaware. Public docket record.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Farxiga prescribing information. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. USPTO.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).